Equillium, Inc. has announced the filing of a prospectus supplement with the U.S. Securities and Exchange Commission for the offer and sale of its common stock worth up to $75 million. This move is part of an existing Open Market Sale Agreement with LifeSci Capital LLC, originally dated October 5, 2023, and amended on August 3, 2025. The latest prospectus supplement updates the previously issued ATM Prospectus, which detailed the sale of up to $21.95 million in shares. Equillium has already sold 1,719,485 shares, generating $0.96 million in gross proceeds under the arrangement. The prospectus supplement must be read with the ATM Prospectus and is considered incomplete without it.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-209068), on September 19, 2025, and is solely responsible for the information contained therein.